Amgen Inc. (AMGN)

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk.

Tech stocks lagged after a very strong first half of the year, while healthcare led the way.

Following quite encouraging news from the laboratory on Monday, Amgen (AMGN 4.07%) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher...

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.

Over the past year, Apple (AAPL 0.04%) and Amgen (AMGN -0.69%), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds. Apple is stru...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously a...